Skip to main content
Fig. 2 | Alzheimer's Research & Therapy

Fig. 2

From: Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer’s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study

Fig. 2

Participant dispositions for ALZ2002 parent and ALZ2004 extension studies. ADuring the study, due to the observation of elevated liver enzymes in some patients, an urgent safety measure was implemented and atabecestat doses were immediately reduced in all participants which occurred when all participants had completed a minimum of 3 months of treatment and about half of the participants had completed the treatment as planned. For the remaining participants on active treatment, atabecestat 10 mg/day was reduced to 5 mg/day, and atabecestat 50 mg/day was reduced to 25 mg/day

Back to article page